Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Down 16.3% in May

Calliditas Therapeutics AB (publ) (NASDAQ:CALTGet Free Report) was the target of a significant drop in short interest in May. As of May 31st, there was short interest totalling 8,200 shares, a drop of 16.3% from the May 15th total of 9,800 shares. Based on an average daily volume of 12,200 shares, the short-interest ratio is currently 0.7 days.

Calliditas Therapeutics AB (publ) Trading Up 0.5 %

Shares of NASDAQ CALT traded up $0.18 during trading hours on Monday, hitting $38.95. The company’s stock had a trading volume of 2,115 shares, compared to its average volume of 11,206. The company has a debt-to-equity ratio of 8.46, a quick ratio of 2.62 and a current ratio of 2.69. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -21.05 and a beta of 1.77. Calliditas Therapeutics AB has a 12 month low of $15.25 and a 12 month high of $41.90. The business has a 50-day simple moving average of $25.99 and a 200-day simple moving average of $23.56.

Calliditas Therapeutics AB (publ) (NASDAQ:CALTGet Free Report) last posted its earnings results on Thursday, May 23rd. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.74). The business had revenue of $28.43 million during the quarter, compared to the consensus estimate of $35.78 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 160.87% and a negative net margin of 40.19%. On average, analysts anticipate that Calliditas Therapeutics AB will post -0.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. HC Wainwright restated a “neutral” rating and set a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday, May 28th. Stifel Nicolaus reaffirmed a “hold” rating and set a $40.00 price objective (down from $55.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Jefferies Financial Group reaffirmed a “hold” rating and set a $39.00 price objective (down from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Citigroup reaffirmed a “neutral” rating and set a $39.00 price objective on shares of Calliditas Therapeutics AB (publ) in a research note on Friday, May 31st. Finally, Lifesci Capital cut Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 28th. Six investment analysts have rated the stock with a hold rating, According to data from MarketBeat, Calliditas Therapeutics AB (publ) presently has a consensus rating of “Hold” and a consensus price target of $35.00.

Read Our Latest Analysis on CALT

Institutional Trading of Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. acquired a new position in Calliditas Therapeutics AB (publ) (NASDAQ:CALTFree Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 980 shares of the company’s stock, valued at approximately $25,000. Institutional investors and hedge funds own 2.83% of the company’s stock.

About Calliditas Therapeutics AB (publ)

(Get Free Report)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.

Recommended Stories

Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.